BiomX (NYSEMKT:PHGE) Stock Price Down 32.6% – What’s Next?

Shares of BiomX Inc. (NYSEMKT:PHGE) were down 32.6% on Wednesday . The company traded as low as $0.72 and last traded at $0.50. Approximately 53,300 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 81,781 shares. The stock had previously closed at $0.74.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating on shares of BiomX in a report on Friday, May 16th.

BiomX Stock Performance

The stock has a 50-day moving average price of $0.56 and a 200 day moving average price of $0.65. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $13.04 million, a price-to-earnings ratio of -0.66 and a beta of 1.51.

Institutional Trading of BiomX

Several institutional investors and hedge funds have recently made changes to their positions in PHGE. Nantahala Capital Management LLC boosted its stake in BiomX by 44.1% in the 1st quarter. Nantahala Capital Management LLC now owns 2,493,309 shares of the company’s stock worth $1,386,000 after buying an additional 762,709 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of BiomX by 83.8% in the 1st quarter. Alyeska Investment Group L.P. now owns 1,590,738 shares of the company’s stock worth $884,000 after purchasing an additional 725,338 shares during the period. AIGH Capital Management LLC raised its holdings in shares of BiomX by 81.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,566,944 shares of the company’s stock worth $871,000 after purchasing an additional 701,544 shares during the period. Allostery Investments LP raised its holdings in shares of BiomX by 46.1% in the 1st quarter. Allostery Investments LP now owns 940,629 shares of the company’s stock worth $523,000 after purchasing an additional 296,796 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in shares of BiomX in the 4th quarter worth about $314,000. 40.57% of the stock is currently owned by hedge funds and other institutional investors.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.